MedTrace Logo

Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

NCT06199141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 279

Last updated 2024-02-28

No results posted yet for this study

Summary

Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a life-support technique used in patients with most severe acute respiratory distress syndrome (ARDS). ARDS is a life-threatening form of respiratory failure associated with a mortality rate of approximately 40-45%.Despite several studies confirming a real benefit of the use of ECMO in patients with ARDS who are unresponsive to conventional management, ECMO is still a complex and costly treatment that can be exposed to potential complications, such as nosocomial infections (NI).

Conditions

  • Respiratory Distress Syndrome, Adult
  • Multi-antibiotic Resistance

Sponsors & Collaborators

  • Azienda Ospedaliera Mater Domini di Catanzaro

    collaborator UNKNOWN

  • Policlinico di Bari Giovanni XXIII

    collaborator UNKNOWN

  • Azienda Ospedaliera Universitaria Integrata Verona

    collaborator OTHER

  • Fondazione IRCCS San Gerardo di Monza

    collaborator UNKNOWN

  • University of Padova

    lead OTHER

Principal Investigators

  • Andrea Bruni, Prof · Azienda Ospedaliera Mater Domini di Catanzaro

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06199141 on ClinicalTrials.gov